Programs and cores
The Program Director of the University of Michigan SCCOR is Theodore J. Standiford, M.D. The Michigan SCCOR is composed of four hypothesis-driven projects, an Administrative Core, and two distinct but integrated Clinical Cores based at both the University of Michigan and Emory University Hospitals . Select a project for more information:
Summary of programs and cores
Project Number and Title |
Principal Investigator |
Co-investigators |
Project 1 : Dynamic Effects of Chemokines on Systemic Inflammation |
Steven Kunkel, Ph.D. |
Nicholas Lukacs, Ph.D.
Cory Hogaboam, Ph.D.
|
Project 2: Macrophage Activation /Deactivation in ALI |
Theodore Standiford, M.D. |
Andrew Rosenberg, M.D.
Thomas Moore, Ph.D.
Ryan Yates, Ph.D. (Univ of Tennessee ) |
Project 3: Alveolar Mesenchymal Cells in Acute Lung Injury |
Victor Thannickal, M.D. |
Andrew Rosenberg, M.D.
Thomas Moore, Ph.D.
Michael Quasney, M.D., Ph.D. (U Tenn ) |
Project 4: A Randomized Trial of GM-CSF in Patients with ALI |
Robert Paine, M.D. |
Andrew Rosenberg, M.D.
Robert Hyzy, M.D. |
Core A: Clinical Core |
Robert Hyzy, M.D.
Marc Moss, M.D. (Emory site) |
Andrew Rosenberg, M.D.
William Bria, M.D.
Wei Wei, Ph.D.
Leslie Quint, M.D.
Aine Kelly, M.D.
Gregory Martin, M.D. (Emory) |
Administrative Core |
Theodore Standiford, M.D.
Mary Malec (Program Coordinator) |
|
In sum, our SCCOR represents a unique multidisciplinary and multicenter collaboration that unites a diverse group of investigators with expertise in the clinical and basic investigation of ALI, as well as provides access to a large population of ALI/ARDS patients to ensure successful completion of the proposed studies. The performance of studies proposed in this application will provide important insights into the regulation of pulmonary inflammation and repair in ALI, which may lead to novel approaches in both the assessment and treatment of this devastating disease. This bench to bedside approach has already culminated in a therapeutic trial assessing the effect of one such factor (GM-CSF) in the treatment of patients with ALI/ARDS.
|
